Denkert et al. also reported the prognosis of HER2-low and HER2-zero BC, and according to their study, the prognosis of HER2-low BC was statistically significantly superior to HER2-zero BC, especially in HR-negative patients (Denkert et al., 2021). This evidence concerns the gene ERBB2 and breast cancer.